Page 66 - IMO-1-1

Innovative Medicines & Omics Antioxidant nanomedicines for therapies

doi: 10.1111/j.1440-1843.2008.01447.x Two randomised trials. Lancet. 2011;377(9779):1760-1769.
293. Holguin F. Oxidative stress in airway diseases. Ann Am doi: 10.1016/S0140-6736(11)60405-4
Thorac Soc. 2013;10 Suppl: S150-S157.
305. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine
doi: 10.1513/AnnalsATS.201305-116AW in idiopathic pulmonary fibrosis. N Engl J Med.
294. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral 2005;353(21):2229-2242.
pneumonia. Lancet. 2011;377(9773):1264-1275. doi: 10.1056/NEJMoa042976
doi: 10.1016/S0140-6736(10)61459-6 306. Nagao S, Taguchi K, Sakai H, et al. Carbon monoxide-
295. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of bound hemoglobin-vesicles for the treatment of
global seasonal influenza-associated respiratory mortality: bleomycin-induced pulmonary fibrosis. Biomaterials.
A modelling study. Lancet. 2018;391(10127):1285-1300. 2014;35(24):6553-6562.
doi: 10.1016/S0140-6736(17)33293-2 doi: 10.1016/j.biomaterials.2014.04.049
296. Hood ED, Chorny M, Greineder CF, Alferiev IS, Levy RJ, 307. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN,
Muzykantov VR. Endothelial targeting of nanocarriers Ames BN. Bilirubin is an antioxidant of possible physiological
loaded with antioxidant enzymes for protection against importance. Science. 1987;235(4792):1043-1046.
vascular oxidative stress and inflammation. Biomaterials. doi: 10.1126/science.3029864
2014;35(11):3708-3715.
308. Keum H, Kim D, Kim J, et al. A bilirubin-derived
doi: 10.1016/j.biomaterials.2014.01.023 nanomedicine attenuates the pathological cascade of
297. Huang Y, Liu Z, Liu C, Zhang Y, Ren J, Qu X. Selenium- pulmonary fibrosis. Biomaterials. 2021;275:120986.
based nanozyme as biomimetic antioxidant machinery. doi: 10.1016/j.biomaterials.2021.120986
Chemistry. 2018;24(40):10224-10230.
309. Albano GD, Gagliardo RP, Montalbano AM, Profita M.
doi: 10.1002/chem.201801725 Overview of the mechanisms of oxidative stress: Impact in
298. Li J, Zhou ZA, Liu XM, et al. Material-herbology: An inflammation of the airway diseases. Antioxidants (Basel).
effective and safe strategy to eradicate lethal viral-bacterial 2022;11(11):2237.
pneumonia. Matter. 2021;4(9):3030-3048. doi: 10.3390/antiox11112237
doi: 10.1016/j.matt.2021.07.001 310. Kluchova Z, Tkacova R. The role of oxidative stress in lung
299. Liu P, Ji P, Wang L, Guo H, Huo M, Shi J. Concurrent injury induced by cigarette smoke. Biologia. 2006;61(6):643-650.
antibiosis and anti-inflammation against bacterial doi: 10.2478/s11756-006-0135-4
pneumonia by zinc hexacyanoferrate nanocatalysts.
Biomaterials. 2022;289:121768. 311. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med.
2001;344(5):350-362.
doi: 10.1016/j.biomaterials.2022.121768
doi: 10.1056/NEJM200102013440507
300. Martinez FJ, Collard HR, Pardo A, et al. Idiopathic
pulmonary fibrosis. Nat Rev Dis Primers. 2017;3(1):17074. 312. Alangari AA. Corticosteroids in the treatment of acute
asthma. Ann Thorac Med. 2014;9(4):187-192.
doi: 10.1038/nrdp.2017.74
doi: 10.4103/1817-1737.140120
301. Cheresh P, Kim SJ, Tulasiram S, Kamp DW. Oxidative
stress and pulmonary fibrosis. Biochim Biophys Acta. 313. Kim DE, Lee Y, Kim M, Lee S, Jon S, Lee SH. Bilirubin
2013;1832(7):1028-1040. nanoparticles ameliorate allergic lung inflammation in a
mouse model of asthma. Biomaterials. 2017;140:37-44.
doi: 10.1016/j.bbadis.2012.11.021
doi: 10.1016/j.biomaterials.2017.06.014
302. Ward PA, Hunninghake GW. Lung inflammation and
fibrosis. Am J Respir Crit Care Med. 1998;157(4 Pt 314. Tsoi KM, MacParland SA, Ma XZ, et al. Mechanism of
2):S123-S129. hard-nanomaterial clearance by the liver. Nat Mater.
2016;15(11):1212-1221.
doi: 10.1164/ajrccm.157.4.nhlbi-10
doi: 10.1038/nmat4718
303. Kliment CR, Oury TD. Oxidative stress, extracellular
matrix targets, and idiopathic pulmonary fibrosis. Free 315. Gustafson HH, Holt-Casper D, Grainger DW,
Radic Biol Med. 2010;49(5):707-717. Ghandehari H. Nanoparticle uptake: The phagocyte
problem. Nano Today. 2015;10(4):487-510.
doi: 10.1016/j.freeradbiomed.2010.04.036
doi: 10.1016/j.nantod.2015.06.006
304. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in
patients with idiopathic pulmonary fibrosis (CAPACITY): 316. Bourquin J, Milosevic A, Hauser D, et al. Biodistribution,

Volume 1 Issue 1 (2024) 60 doi: 10.36922/imo.2527